Allurion Technologies, Inc. (ALUR)

Allurion received a NYSE delisting notice due to failing to meet the exchange's continued listing standards, which the company intends to appeal. Allurion received U.S. FDA premarket approval for the Allurion Gastric Balloon System. Allurion announced the exercise of warrants for $3.0 million in gross proceeds. The company announced preliminary Q4 and full-year 2025 results, expecting Q4 revenue of $3.3M–$3.7M and full-year revenue of approximately $15M. Allurion announced a partnership to offer combination therapy with Mounjaro® (tirzepatide) at discounted prices. Allurion announced a strategic distribution partnership with ProSurg Medical in Brazil. Allurion launched AllurionMeds, combining weight loss medications with its AI-native platform. The stock price has experienced a significant decline.

No explicit information regarding demand seasonality for Allurion Technologies, Inc. products and services was found in the provided search results.

Allurion Technologies, Inc. is a medical device company focused on metabolically healthy weight loss. The company's core offering is the Allurion Program, a comprehensive weight loss platform designed to address obesity. The platform includes the Allurion Gastric Balloon, a swallowable, procedure-less intragastric balloon; the Allurion Virtual Care Suite, a digital health platform; and health tracker devices. Allurion aims to provide a non-invasive, effective, and sustainable alternative to traditional weight loss procedures and medications.

Allurion Technologies has a significant global presence, with its products commercially available in 58 countries. The company has a global vision and has expanded its operations across various regions including Spain, France, Turkey, Brazil, Germany, the Netherlands, and the UK. The company recently began training and onboarding partner accounts across the United States, marking a major step in its expansion strategy into the U.S. market.

Allurion Technologies has cultivated a brand reputation as a pioneer in metabolically healthy weight loss, dedicated to ending obesity through innovative, non-invasive solutions. The company emphasizes its full-stack weight loss platform, which combines medical technology with digital health solutions and behavioral support. Allurion has a positive workplace culture, with 85% of employees stating it is a great place to work. The company has faced challenges such as a temporary sales suspension in France and increased competition from GLP-1 drugs, and the recent NYSE delisting notice.

Allurion Technologies Inc. has a notable institutional ownership presence, with 27 institutional owners and shareholders holding a total of 6,823,487 shares, representing 21.39% of the stock. Major institutional owners include RTW Investments, Lp, Lunt Capital Management, Inc., and Toronto Dominion Bank. Michael Davin was noted for insider selling in December 2025.